National base drug catalog landing reveal which mystery!

Recently, the king of the north, there has been a lot of talk about the adjustment of the base drug catalogue.
According to the latest news, the relevant departments in the South on next year's base drug catalog management methods organized a special meeting, the focus of the meeting is to pre-judge next year's base drug adjustment focus on the direction of consideration, focusing on infectious diseases in the use of drugs, chronic diseases and cancer, tumor-to-slow disease drugs, common diseases, while the disease-led direction, mainly look at product value, clinical endpoint indicators of improvement, to be able to cure as the standard.
this meeting, the relevant business representatives put forward some suggestions on the management methods of the base drug catalogue, as follows: 1. The expansion of the base drug catalogue is expected to reach 90%, 80%, 60% hospital staffing ratio requirements.
according to the current national average of 1500 varieties of drugs in each triple-A hospital, the number of base drugs 900 to meet the policy requirements.
2. In order to avoid the integrity risk of enterprises using exclusive specifications to enter the base drug catalogue for welfare, it is recommended to liberalize the specifications of the base drug catalogue and manage them according to the dosage form of the administration route, such as injection needles, powder needles and lipid microballs, which are no longer distinguished and incorporated as if they were included.
3. It is recommended to consult with the State Health Insurance Administration and the Finance Bureau: the products included in the list of basic drugs are directly into the list of medical insurance or the catalogue of medical insurance negotiations, after inclusion in the catalogue of medical insurance is Class A, the reimbursement ratio is higher than Class B or 100% reimbursement, which can reflect the value of the base drug.
4. It is hoped that the selection and evaluation of the list of essential drugs will be combined with evidence of comprehensive drug evaluation, giving priority to drugs that provide evidence of the effectiveness of comprehensive drug evaluation by institutions such as research institutions, national associations and foundations, and hospitals.
in order to mobilize social forces to promote comprehensive clinical evaluation in a comprehensive, rapid and effective manner.
5. Recommendations for the adjustment cycle: 3 years a major adjustment: enterprises are not allowed to declare, new and old drugs are selected for inclusion and transfer out of the expert review, according to the national hospital drug data priority use of the annual amount of more than 1 billion yuan varieties, deputy master Clinical experts above the commission recommended varieties, provincial health committee recommendations, the first-level society recommended varieties to form an alternative library, after several rounds of expert review to form a final catalog;
for three consecutive declarations of drugs not included, if there are no major changes in the field of adaptive treatment, no longer allowed to declare! 6. Hope to be able to add more Chinese medicine, so that the proportion of Chinese and Western medicine balance.
according to the national health care commission's Drug Administration Division 2020 work points show that this year to optimize the catalog selection adjustment process, timely start catalog adjustment work.
Since June 1 this year, the Basic Medical and Health Promotion Law of the People's Republic of China has been put into effect, and it is mentioned in the Drug Supply Guarantee that the State implements the basic drug system and dynamically adjusts the list of essential drugs in accordance with the clinical practice of drugs, changes in drug standards and new drug listings.
The current Measures for the Administration of the National Essential Medicines Directory were revised on the basis of the Measures for the Administration of the National Essential Medicines Catalog (Temporary) (No. 79) formulated by the former Ministry of Health and nine other departments in 2009, and at present, as the situation changes, the adjustment of the current management methods is normal.
First, according to the relevant policy documents, the army hospital has been asseded to the local, the original military district tender (including the whole army, local military regions) has been taken over by the local, then, the current management methods of the requirements for the army hospital is bound to be adjusted.
addition, in the current withdrawal mechanism of the base drug, it is expected to refer to the relevant requirements of the adjustment of the medical insurance catalogue, drug economics and other related factors, the mechanism of the basic drug in and out is more stringent.
It is not difficult to see that the new version of the national base drug on the drug accessability, safety, effectiveness of the trade-off is more than in the past, evidence-based medicine, pharmacoeconomics will become the new version of the basic drug formulation of an important basis, the scientific selection of varieties will be further improved.
review of the path that the National Base Medicines have gone through, the 307 Essential Medicines Directory was issued in 2009 and subsequently published in March 2013 in the National Essential Medicines Directory (2012 edition) (520 Catalogue), with a four-year interval.
685 catalogues currently in force are effective from 1 November 2018.
September 2014, the Opinions on Further Strengthening the Administration of the Use of Medicines in Primary Health Care Institutions were issued, which mentioned that the addition of non-catalog drugs on a provincial (district, city) unit is a phased measure in the early stages of the implementation of the basic drug system.
the 2012 edition of the National Essential Medicines Directory basically adapts to the needs of primary drug use and does not encourage new additions.
urban community health service centers and rural township hospitals may be equipped with a certain number or proportion of drugs from the medical insurance (new agricultural joint) drug reimbursement catalogue to meet the needs of patients for drug use, and implement zero-rate sales.
In 2017, the Guangdong Provincial Health and Family Planning Commission issued a "Notice on Further Clarifying the Requirements of the Basic Drug System in Our Province", boldly subverting the "Basic Drug System" which has been pursued for many years since the reform, and this document was issued in 2014 as mentioned earlier. The State Health and Planning Commission issued "on the further strengthening of primary health care institutions drug use management advice" in the background, especially in the provinces have introduced relevant policies to support the procurement of non-base drugs in the environment of primary medical institutions, in Guangdong urban and rural health insurance together as one of the background, Guangdong primary drug use finally greatly liberalized, which is a blessing.
the emergence of a list of commonly used medicines at the grass-roots level reveals the fact that for many years the scope of commonly used drugs at the grass-roots level has long exceeded the national list of essential medicines.
The level of China's economic and social development in the 21st century is already among the upper-middle-income countries (the World Bank's sub-grouping criteria are between US$4,126 and US$12,735 per capita, and China's GDP per capita in 2015 has reached about US$7,900), which is bound to generate diversified medical needs.
and an ageing population have contributed to the growth of medical needs.
March 13, 2018, the State Council's reform plan for the majority system was announced.
In accordance with the plan, the National Health and Health Commission will be established, the National Health and Family Planning Commission will no longer be retained, the State Health and Safety Administration will be established, and the State Administration of Market Supervision and Administration will be established separately, and the State Food and Drug Administration will no longer be retained.
this context, the 2018 edition of the National List of Base Medicines (685) was officially announced.
means that China will still maintain the "double catalogue" of essential drugs and basic health insurance.
the NHS is required to "pick up the baton" of medicare payments for the essential drugs catalogue.
At present, the current national list of basic drugs 685, from the original 520 to 685 kinds, of which 417 kinds of Western medicine, 268 kinds of traditional Chinese medicine (including ethnic medicine), in terms of drug use structure, highlighting common diseases, chronic diseases and heavy burden, major diseases and public health and other basic drug needs, pay attention to children and other special groups of drugs, new varieties include 12 kinds of cancer drugs, clinically urgent need for children's drug use 22.
, but overall, especially for children and medicines for major diseases, there is still a greater likely to be included in the 2021 list of new base drugs.
From the current point of view, the base drug 986 has gradually begun to implement in the relevant provinces, some of the original provincial base-based drugs have been gradually cleared out of the market, strict requirements for the use of state-based equipment requirements have gradually taken root in the top-down medical institutions.
At present, if the relevant information is true, it is expected that the relevant parties will speed up the revision of the basic drug catalog management methods, urge the early birth of a new version of the national base medicine, on the other side will be for the base drug catalog of the volume of procurement (such as the current Hebei, Guangdong, Shenzhen and other places to carry out the volume of procurement), and strive to early through the basic basic drug species to take the lead in the realization of real price excavation work, so as to provide strong support for the development of medical insurance payment standards.